Equities

Journey Medical Corp

DERM:NAQ

Journey Medical Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.17
  • Today's Change0.05 / 0.98%
  • Shares traded6.21k
  • 1 Year change+108.47%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 17:17 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments273249
Total Receivables, Net152823
Total Inventory10149.86
Prepaid expenses3.593.312.44
Other current assets, total------
Total current assets567884
Property, plant & equipment, net0.100.190.09
Goodwill, net------
Intangibles, net202713
Long term investments------
Note receivable - long term------
Other long term assets0.010.100.15
Total assets7710597
LIABILITIES
Accounts payable183723
Accrued expenses202023
Notes payable/short-term debt000
Current portion long-term debt/capital leases3.005.195.32
Other current liabilities, total0.055.03--
Total current liabilities426752
Total long term debt15213.63
Total debt18268.95
Deferred income tax------
Minority interest------
Other liabilities, total0.010.110.01
Total liabilities568855
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital938581
Retained earnings (accumulated deficit)(72)(69)(39)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity201742
Total liabilities & shareholders' equity7710597
Total common shares outstanding191817
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.